KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Interest Expenses (2016 - 2020)

Historic Interest Expenses for Nektar Therapeutics (NKTR) over the last 11 years, with Q2 2020 value amounting to $647000.0.

  • Nektar Therapeutics' Interest Expenses fell 8763.14% to $647000.0 in Q2 2020 from the same period last year, while for Mar 2021 it was $647000.0, marking a year-over-year decrease of 9709.71%. This contributed to the annual value of $6.9 million for FY2020, which is 6785.08% down from last year.
  • As of Q2 2020, Nektar Therapeutics' Interest Expenses stood at $647000.0, which was down 8763.14% from $6.2 million recorded in Q1 2020.
  • In the past 5 years, Nektar Therapeutics' Interest Expenses ranged from a high of $6.2 million in Q1 2020 and a low of $647000.0 during Q2 2020
  • For the 5-year period, Nektar Therapeutics' Interest Expenses averaged around $5.2 million, with its median value being $5.4 million (2018).
  • Its Interest Expenses has fluctuated over the past 5 years, first skyrocketed by 3664.4% in 2016, then crashed by 8763.14% in 2020.
  • Nektar Therapeutics' Interest Expenses (Quarter) stood at $5.6 million in 2016, then grew by 1.5% to $5.6 million in 2017, then decreased by 3.87% to $5.4 million in 2018, then grew by 0.24% to $5.4 million in 2019, then crashed by 88.08% to $647000.0 in 2020.
  • Its Interest Expenses stands at $647000.0 for Q2 2020, versus $6.2 million for Q1 2020 and $5.4 million for Q4 2019.